Assembly Biosciences, Inc. reported $75M of revenue over the trailing twelve months, +125% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $75M (to Q2 2026). Net income: −$42K, trailing twelve months to Q2 2026. Free cash flow: −$39M, trailing twelve months to Q2 2026. Operating margin: −60%, trailing twelve months to Q2 2026.

ASMBAssembly Biosciences, Inc.

Healthcare

$19.78-30% 1Y

$19.78

$19.7852 weeks$38.50

Latest close: a new 52-week lowOct 23, 2026what changed →

ASMB as reported

Assembly Biosciences, Inc. reported $75M of revenue over the trailing twelve months, +125% on the year before. 8 reported series are charted on this page, each one as filed.

$75M

Revenue, trailing twelve months · to Q2 2026 · +125% against the twelve months before

Net income: −$42K
Net income · −100% year on year · trailing twelve months to Q2 2026
Free cash flow: −$39M
Free cash flow · −31% year on year · trailing twelve months to Q2 2026
Operating margin: −60%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ASMB, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$75M	+125%	Q2 2026
Net income	−$42K	−100%	Q2 2026
EPS	$1.02	−118%	Q2 2026
Operating margin	−60%	n/a	Q2 2026
Net margin	−43%	n/a	Q2 2026
ROE	−6.8%	n/a	Q2 2026
ROA	−5.3%	n/a	Q2 2026
Free cash flow	−$39M	−31%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.